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Interleukin (IL)-23 is a heterodimeric cytokine that shares the identical p40 subunit as IL-12 
but exhibits a unique p19 subunit similar to IL-12 p35. IL-12/23 p40, interferon 
 
 
 
 (IFN-
 
 
 
), 
and IL-17 are critical for host defense against 
 
Klebsiella pneumoniae.
 
 In vitro, 
 
K. pneumoniae
 
–
pulsed dendritic cell culture supernatants elicit T cell IL-17 production in a IL-23–dependent 
manner. However, the importance of IL-23 during in vivo pulmonary challenge is unknown. 
We show that IL-12/23 p40–deficient mice are exquisitely sensitive to intrapulmonary 
 
K. pneumoniae
 
 inoculation and that IL-23 p19
 
 
 
/
 
 
 
, IL-17R
 
 
 
/
 
 
 
, and IL-12 p35
 
 
 
/
 
 
 
 mice also 
show increased susceptibility to infection. p40
 
 
 
/
 
 
 
 mice fail to generate pulmonary IFN-
 
 
 
, 
IL-17, or IL-17F responses to infection, whereas p35
 
 
 
/
 
 
 
 mice show normal IL-17 and IL-17F 
induction but reduced IFN-
 
 
 
. Lung IL-17 and IL-17F production in p19
 
 
 
/
 
 
 
 mice was 
dramatically reduced, and this strain showed substantial mortality from a sublethal dose of 
bacteria (10
 
3
 
 CFU), despite normal IFN-
 
 
 
 induction. Administration of IL-17 restored 
bacterial control in p19
 
 
 
/
 
 
 
 mice and to a lesser degree in p40
 
 
 
/
 
 
 
 
 
mice, suggesting an 
additional host defense requirement for IFN-
 
 
 
 in this strain. Together, these data demonstrate 
independent requirements for IL-12 and IL-23 in pulmonary host defense against 
 
K. 
pneumoniae,
 
 the former of which is required for IFN-
 
 
 
 expression and the latter of which is 
required for IL-17 production.
 
To perform its primary function of gas exchange,
the mucosal surface of the lung is continuously
exposed to the environment. Given the con-
siderable infectious risk to the host, complex
mechanisms exist to prevent the development
of bacterial pneumonia (1, 2). The immune
system in the lung consists of both innate and
adaptive components, and it is clear these two
systems are highly interdependent for optimal
host defense.
Upon bacterial recognition, innate immune
cells release cytokines such as tumor necrosis
factor 
 
 
 
 to initiate the inflammatory response
(3, 4). Innate effector cells are also important
in the initiation of adaptive immunity by secret-
ing cytokines such as IL-12 (5, 6). A key role
of IL-12 is the induction of IFN-
 
 
 
, an important
cytokine in pulmonary defense against 
 
Klebsiella
pneumoniae
 
 (7, 8). The identification of IL-23
as a cytokine with characteristics similar to, but
distinct from, IL-12 has created particular interest
in deciphering the role of this cytokine in the
immune response to infection (9). IL-23 is
secreted as a heterodimer composed of a p40
subunit identical to that of IL-12 and a unique
p19 subunit that shares sequence homology
with IL-12 p35. IL-23 is expressed predomi-
nantly by stimulated antigen-presenting cells,
including dendritic cells (DCs), peripheral blood
monocytes/macrophages, and brain microglia
cells (9–11). Whereas IL-12 is important in
stimulating IFN-
 
 
 
 production by naive T
cells, IL-23 is reported to elicit IFN-
 
 
 
 from
human memory T cells (9). Recombinant IL-23
can also signal directly on peritoneal macro-
phages to induce tumor necrosis factor 
 
 
 
 and IL-
1
 
 
 
, suggesting that IL-23 acts as an autocrine
proinflammatory cytokine in these cells (11).
The importance of IL-23 during an infectious
challenge is suggested by studies showing that
certain bacterial, fungal, and mycobacterial in-
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fections are less severe in animals lacking the IL-12 p35 sub-
unit compared with those deficient in IL-12/23 p40 (12–
15). Recently, the creation of IL-23 p19
 
 
 
/
 
 
 
 mice has shown
that IL-23 is critical for the generation of memory T cell–
dependent humoral and cell-mediated immune responses to
antigen (16).
In addition, IL-23 stimulates T cell production of IL-17
(IL-17A) and IL-17F (17), cytokines that promote neutro-
philic inflammation through the induction of granuloctye
CSF (G-CSF), granulocyte macrophage CSF, monocyte
chemoattractant protein 1, IL-1
 
 
 
, IL-6, and the neutrophil
chemokines growth-related oncogene-
 
 
 
, IL-8 (human), and
keratinocyte chemoattractant (KC), LPS-induced C-X-C
chemokine (LIX), and macrophage inflammatory protein 2
(MIP-2) (mouse) in a variety of target cells (18–22). We
have shown that IL-17 signaling is critical for maintenance
of a granulopoietic response and survival from pulmonary 
 
K.
pneumoniae
 
 infection (21). More recent work demonstrates
that bone marrow–derived myeloid dendritic cell (mDC)
cultures pulsed with this bacteria secrete IL-23 only if intact
Toll-like receptor 4 (TLR4) is present (23).
However, the role of IL-23 during in vivo pulmonary 
 
K.
pneumoniae
 
 challenge is unknown. We show that IL-23 is a
cytokine critical to host survival during infection and dem-
onstrate that IL-23 is the dominant in vivo stimulus for pul-
monary IL-17 and IL-17F production in this model. Alveo-
lar macrophages (AMs) and pulmonary mDCs are significant
sources of IL-23 during in vitro challenge with this patho-
gen, whereas lung plasmacytoid dendritic cells (pDCs) are
not. Furthermore, defective bacterial clearance in IL-23
p19
 
 
 
/
 
 
 
 mice could be abolished by administration of exoge-
nous IL-17, and this treatment restored lung G-CSF and
LIX production. A more moderate improvement in bacterial
clearance was also observed in IL-12/23 p40
 
 
 
/
 
 
 
 mice,
which are defective in mounting an IFN-
 
 
 
 response, further
demonstrating an IFN-
 
 
 
–independent role of the IL-23/IL-17
axis in host defense.
 
RESULTS
Reduced survival of IL-12– and IL-23–deficient mice during 
pulmonary 
 
K. pneumoniae
 
 challenge
 
IL-12, STAT4, IFN-
 
 
 
, and IL-17 signaling have each been
shown to be critical for host defense against pulmonary 
 
K.
pneumoniae
 
 infection (6, 21, 24). However, the precise role of
IL-12 and IL-23 during infection has not been demonstrated.
To determine the independent requirement for IL-12 and
IL-23 expression in surviving this infection model, we chal-
lenged wild-type (WT), IL-12/23 p40
 
 
 
/
 
 
 
, IL-12p 35
 
 
 
/
 
 
 
,
and IL-23 p19
 
 
 
/
 
 
 
 mice with 10
 
4
 
 CFU 
 
K. pneumoniae
 
. IL-12/
23 p40
 
 
 
/
 
 
 
 mice showed a rapid decline in survival (P 
 
 
 
 0.05
by log rank test compared with WT) (Fig. 1 A). Survival was
also diminished in IL-17R
 
 
 
/
 
 
 
, IL-23 p19
 
 
 
/
 
 
 
, and IL-12
p35
 
 
 
/
 
 
 
 mice compared with wild-type C57BL/6 mice. To
further characterize the requirement of IL-23 in pulmonary
host defense, we next challenged WT and p19
 
 
 
/
 
 
 
 mice with
a sublethal dose of bacteria (10
 
3
 
 CFU). As shown in Fig. 1 B,
IL-23–deficient mice display marked sensitivity to a normally
well-controlled bacterial inoculum. Together, these results
suggest that both IL-12 and IL-23 are critical for pulmonary
host defense against 
 
K. pneumoniae.
 
Bronchoalveolar lavage (BAL) cell IL-23 p19, IL-12/23 
p40, and IL-12 p35 mRNA expression following 
 
K. pneumoniae
 
 infection
 
As both IL-12 and IL-23 are critical for host defense in this
model, we analyzed the time course of IL-23 p19, IL-12
p40, and IL-12 p35 gene expression in bronchoalveolar la-
vage (BAL) cells over time following 
 
K. pneumoniae
 
 infection
via real-time reverse-transcription polymerase chain reaction
(RT-PCR). Prior to bacterial challenge, p40 transcripts
were present in BAL cells (Ct 32 
 
 
 
 2.3). In contrast, base-
line IL-12 p35 and IL-23 p19 transcripts were not detected.
Inoculation with 
 
K. pneumoniae
 
 increased expression of all
three genes over baseline levels, though significant increases
in IL-23 p19 transcripts occurred sooner than increases in
p40 or p35 mRNA (Fig. 2 A). IL-12 p35 messenger RNA
(mRNA) did not show significant induction until 16 h after
 
K. pneumoniae
 
 inoculation, suggesting that because p40 tran-
Figure 1. Animals with targeted gene deletion in the IL-12, IL-17, 
and IL-23 signaling pathways demonstrate increased mortality during 
intrapulmonary K. pneumoniae infection. (A) WT C57BL/6, IL-23 p19 / , 
IL-12 p35 / , IL-12 p40 / , or IL-17R /  mice were challenged with 104 
CFU intratracheal K. pneumoniae and survival was recorded every 12 h 
(n   16–20 per group). IL-12 p40 knockout mice showed the greatest sus-
ceptibility to infection (*P   0.01 compared with C57BL/6 [log rank test]). 
Survival differences between IL-23 p19 / , IL-17R / , and IL-12 p35 /  
mice were not statistically significant. (B) WT and p19 /  mice were also 
challenged with a lower dose (103 CFU) of bacteria, demonstrating significant 
mortality in p19 /  mice to a sublethal dose of K. pnuemoniae (*P   0.01 
compared with WT mice; n   10 per group).JEM VOL. 202, September 19, 2005 763
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scripts are already present, BAL cell IL-23 is induced rapidly
and sooner than IL-12 p70 expression. These results were
confirmed at the protein level, because IL-23 was detectable
via ELISA 2 h after K. pneumoniae challenge (173   17 pg/
mL; n   5), whereas IL-12 p70 was undetectable at this
early time point.
Because IL-23 elicits T cell IL-17 production in response
to in vitro K. pneumoniae challenge, we examined the time
course of IL-23 p19, IL-17, and IL-17F mRNA expression
in lung tissue following intrapulmonary infection using real-
time RT-PCR. Transcripts for these genes were undetect-
able at baseline, but significant increases in their expression
were seen following infection, with p19 mRNA increasing
as early as 2 h and peaking at 16 h after challenge (Fig. 2 B).
IL-23 expression in lung cell subpopulations in response 
to K. pneumoniae
Because AMs are critical to pulmonary host defense against
K. pneumoniae (25), express TLR4 (26), and are resident in
the alveoli, we hypothesized that they are an early source of
IL-23 in response to infection. AM production of IL-23 was
assayed using IL-17 production by splenocytes as a bioassay
(17, 21, 27). AMs from WT, IL-23 p19 / , IL-12 p35 / ,
and IL-12/23 p40 /  animals were recovered by BAL of
naive animals and treated with pathogen in vitro as described
in Materials and methods. Cell-free supernatants collected
24 h after WT AM culture with K. pneumoniae showed sig-
nificant IL-17–inducing capacity when transferred onto
splenocyte cultures, whereas IL-12/23 p40 /  or IL-23 p19 / 
AM culture supernatants failed to stimulate splenocyte IL-17
production (Fig. 3 A). Culture supernatants from p35 / 
AMs stimulated splenocyte IL-17 production to a signifi-
cantly greater extent than did supernatants from WT AMs.
In contrast, supernatants from bacteria-stimulated AM did
not induce splenocyte IFN-  production, and IL-12 p70
was not detectable in these AM supernatants (IL-12 p70
limit of detection 8 pg/mL; unpublished data). These data
demonstrate a strict requirement for IL-23 in AM-induced
IL-17 stimulation, and demonstrate that, in vitro, IL-12 is
not a significant AM product in response to K. pneumoniae
over this time course.
Bone marrow–derived cultures of mDCs and pDCs have
recently been shown to differ in their ability to drive T cell
activation in response to LPS, likely as a result of differential
TLR4 expression by these DC subsets (28). Whether differ-
ences exist in the ability of lung resident DC populations to
express IL-23 in response to K. pneumoniae is unknown. Us-
ing FACS, we isolated both mDCs and pDCs from lung di-
gests of naive C57BL/6 mice to more than 95% purity. AMs
and DCs were cultured with bacteria or media control for
Figure 2. Cytokine mRNA expression following pulmonary K. pneu-
moniae infection. Animals were administered 104 CFU bacteria and killed 
at specified time points. BAL cell pellet and lung homogenate mRNA were 
assayed via real-time RT-PCR. (A) Increases in BAL cell IL-23 p19, IL-12/23 
p40, and IL-12 p35 mRNA expression during infection (n   4–5 per group). 
(B) Whole lung tissue IL-23 p19, IL-17, and IL-17F mRNA expression following 
infection (n   4–5 per group). Data are normalized for 18s ribosomal RNA 
content and plotted as fold change over baseline (time 0) expression. 
*Earliest significant (P   0.05) increase in expression compared with time 
zero transcripts. Error bars represent mean   SD.
Figure 3. AM IL-23 expression is required for induction of spleno-
cyte IL-17 expression in response to K. pneumoniae. (A) AMs
from naive WT, p35 / , p40 / , and p19 /  mice were recovered via 
BAL and exposed in vitro to K. pneumoniae. After 24 h, supernatants 
were harvested, centrifuged, and placed onto adherent cell-depleted 
WT splenocytes for 24 h to assay IL-17 induction (n   5 per group; 
*P   0.05 compared with media control). (B) IL-23 p19 mRNA expression 
in unexposed mDCs (mDC-control) or pDCs (pDC-control) or mDCs, 
AMs, and pDCs following 2-h in vitro exposure to K. pneumoniae. Data 
are expressed as fold increase in p19 expression compared with mDC- 
or pDC-control (n   4–5 per group; *P   0.05 compared with mDC-
control). Error bars represent mean   SD.IL-23 AND PULMONARY K. PNEUMONIAE INFECTION | Happel et al. 764
2 h. mDCs exhibited an almost twofold greater IL-23 p19
mRNA expression compared with AMs, whereas pDCs ex-
pressed approximately one tenth the level seen in mDC cul-
tures and one fourth the level of p19 transcripts seen in AM
cultures (Fig. 3 B). IL-23 p19 transcripts were not detected
in cells not exposed to bacteria.
Differential requirements for IL-12 and IL-23 in pulmonary 
IFN- , IL-17, and IL-17F expression
Given these survival phenotypes and the known require-
ments for IFN-  and IL-17 in pulmonary host defense
against this infection, we sought to determine the in vivo
requirements for IL-12 and IL-23 signaling in pulmonary
IL-17, IL-17F, and IFN-  expression. WT, IL-12 p35 / ,
IL-12/23 p40 / , and IL-23 p19 /  animals were adminis-
tered 104 CFU K. pneumoniae via intratracheal injection.
Transcripts for IL-17 and IL-17F were undetectable in lung
tissue before bacterial challenge (unpublished data). Sixteen
hours after infection, WT and IL-12 p35 /  mice demon-
strate significant induction of both IL-17 (Fig. 4 A) and IL-
17F (Fig. 4 B), indicating IL-12 is unnecessary for the pul-
monary IL-17/17F responses to this pathogen. In contrast,
p40 /  and IL-23 p19 /  mice had significantly reduced
levels of IL-17 and IL-17F transcripts in lung tissue after
bacterial challenge. These results were confirmed at the pro-
tein level for IL-17 in lung homogenate 24 h after bacterial
challenge (Fig. 4 C). IL-12 is, however, required to gener-
ate the IFN-  response to infection, as evidenced by signifi-
cantly attenuated lung IFN-  levels in p35 /  and p40 / 
mice (Fig. 4 D). IFN-  levels were not significantly reduced
in the IL-23 p19 /  mice. To confirm the dispensable na-
ture of IL-23 in mediating IFN-  induction, whole lung
RNA was assayed for IFN-  transcripts 24 h after infection
and was found to be similar in IL-23 p19 /  and WT con-
trol mice (Fig. 4 E).
Cytokines and chemokines up-regulated by IL-17 
are reduced in IL-23 p19–deficient mice during 
K. pneumoniae infection
Because IL-23 is critical for lung IL-17 induction after gram-
negative challenge, we analyzed whether inflammatory me-
diators known to be up-regulated by IL-17 (such as G-CSF,
IL-6, MIP-2, KC, and LIX) (21, 22) were also reduced in
IL-23 p19 /  mice during infection. At 24 h postinoculation,
lungs of knockout mice contained significantly attenuated
levels of G-CSF, IL-6, MIP-1 , and the ELR  CXC che-
mokines KC, MIP-2, and LIX compared with WT controls
(Fig. 5 A and B), although differences in IL-1  were not sig-
nificant. These data are similar to those observed in IL-17
receptor–deficient mice (21), further supporting a functional
Figure 4. IL-23 expression is required for lung IL-17 and IL-17F 
expression, whereas IL-12 is necessary for IFN-  induction in response 
to K. pneumoniae infection. WT, p35 / , p40 / , and p19 /  mice were 
infected with 104 CFU K. pneumoniae and killed 24 h after infection. 
(A, B) Whole lung homogenate IL-17 (A) and IL-17F (B) mRNA expression 
as measured via real-time RT-PCR. (C) Whole lung homogenate IL-17 protein 
expression in repeat experiments. (D) Lung homogenate IFN-  content in 
response to infection, indicating IL-23 is not sufficient to induce IFN-  in 
the absence of IL-12. (E) Lung homogenate IFN-  mRNA 24 h after K. 
pneumoniae infection confirms equivalent IFN-  expression in WT and 
IL-23 p19 /  mice (n   6 per group; *P   0.05 compared with WT). Error 
bars represent mean   SD.JEM VOL. 202, September 19, 2005 765
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role for the IL-23/IL-17 axis in specific components of the
inflammatory response to this pathogen.
Rescue of IL-23 p19 knockout mice with IL-17 restores 
bacterial host defense and G-CSF and LIX levels 
in IL-23 p19 knockout mice
To confirm a role for IL-17 in host defense against K. pneu-
moniae in IL-23 p19 /  mice, we performed rescue experi-
ments using recombinant murine IL-17 administered in-
tratracheally 12 h after infection, the time at which IL-17
becomes detectable in BAL fluid in this model (29). Mice
were killed 24 h later. For these experiments, we adminis-
tered a dose of 1.5  g of recombinant IL-17; this resulted in
a mean level of IL-17 in BAL fluid 12 h after administration
of 482   92 pg/mL, which is a physiological concentration
of IL-17 in this model (29). Vehicle treated IL-23 p19 / 
mice demonstrate significantly higher burdens of K. pneumo-
niae in lung tissue as well as greater dissemination to the
spleen 36 h postinoculation compared with WT control
mice (Fig. 6 A). Administration of IL-17 significantly im-
proved lung antibacterial host defense in IL-23 p19 /  mice
and significantly reduced dissemination to the spleen in both
WT and p19 /  mice. This enhanced clearance was associ-
ated with an increase in G-CSF and KC levels in BAL fluid,
but not in IL-6, as measured 24 h after IL-17 treatment (Fig.
6 B). Among the CXC chemokines, IL-17 administration
had the most dramatic effect on increasing LIX in IL-23
p19 /  mice (Fig. 6 B). We did not detect any differences
in IFN-  in BAL fluid at this 24-h time point (12.3   3.9
pg/mL in WT vs. 9.8   5.4 pg/mL in IL-23 p19 /  mice).
However, to investigate whether restoration of IL-17 signal-
ing in the absence of IFN-  was at least partially protective,
we performed a similar rescue experiment in IL-12/23 p40
mice. In this setting, IL-17 delivery resulted in a more mod-
est yet significant improvement in both lung and splenic
clearance of K. pneumoniae (Fig. 6 C), although the effect
was more modest compared with results observed in IL-23
p19 /  mice (Fig. 6 A).
DISCUSSION
Our current studies show that IL-23 is required for the in
vivo pulmonary IL-17 and IL-17F response to K. pneumoniae
infection. These results are novel in the light of previous
work suggesting other cytokine signals, namely IL-15, are
responsible for the pulmonary IL-17 response to lipopolysac-
charide (30). Although IL-15 appears to play a role in IL-17
induction in other models of inflammation (31–33), our cur-
rent data demonstrate a strict requirement for IL-23 in pul-
Figure 5. IL-23 p19 /  mice have reduced cytokine and chemokine 
responses to K. pneumoniae infection. Whole lung cytokine and 
chemokine content were measured in lung homogenates 24 h after 104 
CFU K. pneumoniae delivery. Values are normalized to homogenate protein 
concentration (n   6 per group; *P   0.05 compared with WT). Error bars 
represent mean   SD.
Figure 6. Defects in pulmonary host defense in IL-23 p19 /  mice 
are rescued by IL-17 treatment. WT C57BL/6 or IL-23 p19 /  mice were 
challenged with 104 K. pneumoniae followed by intratracheal administration 
of 1.5  g recombinant murine IL-17 (or phosphate-buffered saline vehicle) 
12 h later. Animals were then killed 24 h after rmIL-17 (or vehicle) delivery. 
(A) IL-17 improves bacterial clearance in IL-23 p19 /  mice. (B) IL-17 restores 
pulmonary concentrations of G-CSF, KC, and LIX in IL-23 p19 /  mice. 
(C) IL-17 partially improves bacterial clearance in IL-12 p40 /  mice. 
*P   0.05 compared with WT vehicle-treated control. **P   0.05 compared 
with vehicle-treated group of same genotype (n   4–6 per group). Error 
bars represent mean   SD.IL-23 AND PULMONARY K. PNEUMONIAE INFECTION | Happel et al. 766
monary IL-17/17F induction in response to K. pneumoniae
challenge. Our current work also identifies two potential
sources of IL-23 in the lung—AMs and mDCs—and sug-
gests IL-23 functions very early in lung response to pathogen
compared with IL-12. As early as 4 h after in vitro exposure
to bacteria, media from AM culture stimulates splenocyte
IL-17 production, indicating a rapid induction of bioactive
IL-23 (unpublished data). In contrast, IL-12 remained unde-
tectable in AM culture supernatants even 24 h after in vitro
challenge, and these supernatants did not induce splenocyte
IFN-  expression. These findings are consistent with prior
work showing that AMs produce little or no IL-12 p70 in
response to isolated challenge with K. pneumoniae or LPS (5,
24). Hence, AM may be more important in initiating the
early “ThIL-17” response to this pathogen rather than direct-
ing T cells into Th1 polarization (34).
In vivo, up-regulation of IL-23 p19 in BAL cells is seen
as early as 2 h after K. pneumoniae infection. Cells obtained
by BAL at this time are still more than 95% AMs, implicat-
ing these cells as the likely source of early IL-23 expression
in the alveolar compartment, because they express p40
mRNA even before infection. Hence, induction of p19
transcription likely regulates the onset of IL-23 production
in air spaces. The early increase in BAL cell p19 mRNA is
followed by greater expression 16–24 h after infection, a pat-
tern observed in both BALF cells and lung homogenate.
Whether this finding is due to the alveolar recruitment of
additional cell types expressing IL-23 p19 or increased AM
gene expression is unknown.
Interestingly, we observed greater splenocyte IL-17 in-
duction from bacteria-pulsed IL-12 p35 /  AM conditioned
media compared with WT AM. A regulatory role for IL-12
in IL-23–mediated signaling has been previously demon-
strated (17), because IL-12 and IL-23 share a common p40
subunit and both require IL-12R 1 binding to signal. How-
ever, we were unable to measure IL-12 p70 in bacteria-stim-
ulated AM supernatants, regardless of genotype. One hy-
pothesis is that AM production of bioactive IL-23 is greater
in p35 /  AMs, because more intracellular p40 is available to
combine with p19. In support of this is, it has been shown
that the elaboration of IL-12 p70 in AMs is under posttran-
scriptional control, and a second stimulus (such as IFN- ) (5)
is required for AM release of IL-12 p70 heterodimer in re-
sponse to LPS. Of note, higher IL-17 levels in IL-12 p35 / 
mice was not observed in vivo. However, deficient STAT1
signaling results in augmented IL-23 and IL-17 expression in
the context of respiratory syncytial virus infection (35).
Our prior work has shown that TLR4 signaling is re-
quired for early IL-23 p19 and IL-17 mRNA expression in
the lung challenged with K. pneumoniae (23). The greater
up-regulation in p19 mRNA seen in mDCs compared with
pDCs also supports a TLR4-dependent mechanism for IL-
23 expression in this model, because granulocyte macro-
phage CSF–treated, bone marrow–derived mDCs are re-
ported to express greater amounts of TLR4 and are more
responsive to LPS than Flt3 ligand-generated pDCs (28). Our
data lead us to speculate that mDCs play an important role in
the IL-17 recall response to bacterial challenge as mDCs
readily migrate to draining lymph nodes upon antigen cap-
ture, a function not readily shared by AMs (36). The subse-
quent T cell expansion, IL-17 expression, and augmented
neutrophil recruitment as a result of the IL-23/IL-17 axis
may represent a novel “cross-talk” loop between innate and
adaptive pulmonary immunity, which enables the infected
lung to more rapidly contain infection.
Although IL-12 p35 was not required for the pulmonary
IL-17 response to K. pneumoniae, it was requisite for IFN- 
expression in this infection. This finding is consistent with
the well-studied stimulatory effect of IL-12 on IFN-  ex-
pression (37) as well as prior work that demonstrates the re-
quirement of intact IL-12 for the pulmonary IFN-  response
to infection (38). The inability of IL-23 to induce pulmo-
nary IFN-  expression in the absence of IL-12 is consistent
with previous work showing the failure of recombinant IL-
23 to induce splenocyte IFN-  expression, despite up-regu-
lation of IL-17 by this cytokine (17). These observations are
likely the result of differential receptor affinity and intracel-
lular signaling events induced by IL-12 and IL-23. IL-12
binding to the IL-12R 1/R 2 complex predominantly ac-
tivates STAT4. In contrast, IL-23 binds to the IL-23R/IL-
12R 1 complex and induces STAT3, STAT1, and possibly
STAT3/STAT4 heterodimer nuclear translocation, while
only weakly activating STAT4 (39).
Our finding of decreased survival following pulmonary
K. pneumoniae infection in both p35 /  and p40 /  mice is
consistent with other reports of the importance of intact IL-
12 signaling in this infection model. The early and universal
mortality observed in the p40 /  group compared with other
strains suggests roles for both IL-12 and IL-23 in host defense.
That a normally sublethal pathogen dose imparts 60% mortal-
ity in IL-23 p19 /  animals confirms the critical requirement
for this cytokine in surviving pulmonary K. pneumoniae infec-
tion. Bacterial clearance could be significantly enhanced in
IL-23 p19 /  mice by administration of recombinant IL-17
at 12 h into the infection, and this treatment restored G-CSF
and LIX production without correcting IL-6 expression.
These data suggest that the absence of IL-17 signaling in
p19 /  mice mediates the observed phenotype and that IL-
17–induced IL-6 signaling is not a critical component of host
defense in this infection model. Despite the absence of IL-12
and markedly diminished lung IFN-  induction in IL-12/23
p40 /  mice, IL-17 treatment still reduced significantly the
high bacterial burden observed in these mice, further suggest-
ing IL-17 plays a significant role in host defenses in this
model independent of IL-12/IFN-  signaling.
We recognize that the current study has important limita-
tions. Namely, we have not identified the specific effector im-
mune functions defective in the absence of IL-23 signaling.
Because IL-17 and IL-17F elicit neutrophil recruitment in the
lung (40), defects in the number or function of these cells mayJEM VOL. 202, September 19, 2005 767
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also underlie the observed phenotype. Impaired antimicrobial
peptide production may also contribute to enhanced mortal-
ity, as IL-17 signaling has also been shown to induce airway
epithelial cell expression of mucin and   defensin 2 proteins,
molecules important in bacterial clearance (41–43).
Our data support a critical role for IL-23 and IL-17 in
early host resistance to K. pneumoniae independent of IL-12
and IFN- . It is possible that IL-23 and the subsequent IL-
17 pathway have evolved to handle extracellular gram-nega-
tive bacterial challenges, because IL-17 is not required for
host resistance against intracellular organisms such as Listeria
monocytogenes or Mycobacterium tuberculosis (Kolls et al., un-
published observations), whereas IL-12 and IFN-  have
been shown to be critical for host resistance against these
pathogens (44–46). Moreover, because IL-23 is critical for
autoimmune diseases such as arthritis and multiple sclerosis
(47), our data suggest that targeting IL-23 p19 would be less
immunosuppressive than IL-12/23 p40.
MATERIALS AND METHODS
Mice. Specific pathogen-free C57BL/6, IL-12 p35 / , and IL-12/23
p40 /  mice were purchased at 6–8 wk of age (The Jackson Laboratory).
IL-23 p19 /  mice were provided by N. Ghilardi. All mice were housed in
specific pathogen-free rooms within the animal care facilities of the Louisi-
ana State University Health Sciences Center or Children’s Hospital of Pitts-
burgh under Institutional Animal Care and Use Committee-approved pro-
tocols. Mice were provided with water and food ad libitum and received
12-h light/dark cycles until the date of the experiment.
Infection model. Mice were anesthetized via intraperitoneal ketamine/
xylazine injection. The neck was opened in sterile fashion, and the trachea
was cannulated with a 30-gauge needle. K. pneumoniae strain 43816 sero-
type 2 (American Type Culture Collection) was injected in a volume of 50
 L sterile phosphate-buffered saline (PBS). For IL-17 rescue experiments,
1.5  g of recombinant murine IL-17 (R&D Systems) was delivered via the
intratracheal route in a volume of 50  L sterile PBS following light isoflu-
rane anesthesia. At designated time points, animals were anesthetized and
killed via cardiac puncture. Serial BAL was performed using 10 mL of
Ca2 - and Mg2 -free PBS containing 5 mM glucose as described previously
(21). BAL cell pellets were resuspended in RNeasy lysis buffer (RLT) for
RNA isolation (QIAGEN). Nonlavaged whole lung samples were obtained
via dissection and homogenization (Omni GLH, Omni International) in
PBS containing 0.5% Triton X-100 and protease inhibitor cocktail (Roche
Complete; Roche Applied Science) for protein determinations or in buffer
RLT for RNA isolation.
Cell culture. AMs were obtained for cell culture via BAL of naive mice,
and these cells were more than 95% macrophages as determined by mor-
phology on cytologic examination (unpublished data) for all experiments.
DCs were obtained as follows: after lung lavage for partial depletion of AM,
lungs were finely minced and incubated at 37 C with 1 mg/mL type IV
collagenase (Sigma-Aldrich) for 1 h on a rotating shaker. The cell mixture
was passed through a 40- m nylon mesh filter and centrifuged at 400 g, and
red cells were lysed. The cells were washed with PBS, counted, and stained
with I-Ab, CD11c, CD11b, and CD45R/B220 monoclonal antibodies
(BD Biosciences) after incubation with Fc block. DCs were obtained via
fluorescence-activated cell sorting using the FACSAria cytometer (BD Bio-
sciences). mDCs were defined as IAb , CD11c , CD11b , and B220 ;
pDCs were defined as IAb , CD11c , CD11b , and B220 . Isotype con-
trols were performed to assist in sorting. Cells were resuspended in RPMI
1640 (Invitrogen) supplemented with 10% fetal calf serum. In vitro infec-
tion was performed by adding 107 CFU K. pneumoniae to 105 cells, giving a
multiplicity of infection of 100:1. Splenocytes were obtained from C57BL/6
mice via organ passage through a 70- m nylon mesh filter and centrifuged
at 400 g, and red cells were lysed using NH4Cl. The cells were washed
twice with PBS and plated onto 12-well plates in RPMI 1640   10% FCS
in a 37 C 5% CO2 incubator. After 1 h, nonadherent cells were removed
for use in conditioned media studies. At specified time points after in vitro
infection, AMs and DCs were harvested for mRNA assay, and supernatants
were centrifuged at 20,000 g for 20 min before transfer onto adherent cell-
depleted splenocyte preparations for overnight culture. After 24 h of incu-
bation at 37 C in a 5% CO2 incubator, cells and media from splenocyte cul-
tures were harvested for mRNA and protein assay, respectively.
Real time RT-PCR. Total RNA from lung homogenates and cultured
cells was isolated using the RNeasy mini kit (QIAGEN). Ten nanograms of
total RNA was subjected to one-step RT-PCR using TaqMan linear hy-
drolysis chemistry on the iCycler thermocycler (Bio-Rad). Gene-specific
primers and dual-labeled probe sequences for IL-23 p19, IL-17, IL-17F, IL-
12/23 p40, and IL-12 p35 mRNA and 18s ribosomal RNA (rRNA) were
designed using Beacon Designer 2.12 (Premier Biosoft International) as
follows (primer, primer, probe): IL-17, 5 -GCTCCAGAAGGCCCTC-
AGA-3 , 5 -CTTTCCCTCCGCATTGACA-3 , 5 -ACCTCAACCGT-
TCCACGTCAC-3 ; IL-17F, 5 -GCAGACACTCAGGCTGCATC-3 ,
5 -CCTCCGAAGGACCAGGATTT-3 , 5 -TGCTGTCTTCCTGACC-
CTGGGCAT-3 ; IL-23 p19, 5 -TGGCTGTGCCTAGGAGTAGCA-3 ,
5 -TTCATCCTCTTCTTCTCTTAGTAGATTCATA-3 , 5 -CTCTGC-
ATGCTAGCCTGGAAC-3 ; IL-12 p35, 5 -CCAAGGTCAGCGTTCC-
AACA-3 , 5 -AGAGGAGGTAGCGTGATTGACA-3 , 5 -CCTCACC-
CTCGGCATCCAGCAGC-3 ; IL-12 p40, 5 -ACAGCACCAGCTTC-
TTCATCAG-3 , 5 -TCTTCAAAGGCTTCATCTGCAA-3 , 5 -CAT-
CAAACCAGACCCGCCCAAGAA-3 ; 18s rRNA, 5 -ATTCGAACG-
TCTGCCCTATCA-3 , 5 -GTCACCCGTGGTCACCATG-3 , 5 -TCG-
ATGGTAGTCGCCGTGCCTACC-3 . IFN-  mRNA was assayed using
SYBR Green dye and the gene-specific primers 5 -TCAGCAACAGCA-
AGGCGAAA-3  and 5 -CCGCTTCCTGAGGCTGGAT-3 . A melt curve
analysis was performed after all SYBR runs to ensure single PCR product
formation, and expected IFN-  amplicon size was confirmed via gel elec-
trophoresis of the PCR product. All samples were normalized to 18s rRNA
content. Data are expressed as transcript copy numbers per nanogram of 18s
rRNA (when complementary RNA standards were used) or as fold induc-
tion over baseline, using time zero gene expression levels as reference (48).
Cytokine assays. Lung homogenate and culture supernatant cytokine lev-
els were determined via Bio-Plex cytokine bead array (Bio-Rad Laborato-
ries), with the exception of LIX and IL-23, which were measured via sand-
wich ELISA (R&D Systems and eBioscience, respectively).
Statistical analysis. All data are presented as the mean   SEM. Statistical
analysis was performed with a commercially available statistical software
program (SAS OnlineDoc 9, SAS Institute). Data were tested for differences
using analysis of variance for mixed and random effect models followed by
the Tukey-Kramer range test. Survival analysis was performed using the log
rank test. Statistical significance was set at P   0.05.
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